Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma
LLV is associated with poorer responses to ICIs-based therapy and reduced survival in patients with HBV-related uHCC.
Authors
- Kaiyan Su
- Manhua Zhong
- Guosheng Yuan (ORCID: https://orcid.org/0000-0002-2118-4553)
- Yongru Chen (ORCID: https://orcid.org/0000-0001-6134-3355)
- Rong Li (ORCID: https://orcid.org/0000-0003-0764-3757)
- Jinzhang Chen (ORCID: https://orcid.org/0000-0003-4964-2218)
- Zhanzhou Lin
- Xiaoyun Hu
- Wenli Li (ORCID: https://orcid.org/0000-0002-3532-6444)
- Wei Zhu
- Qi Li (ORCID: https://orcid.org/0000-0002-3930-6715)
- Miaoxian Zhao (ORCID: https://orcid.org/0000-0002-3021-7249)
- Jun Yan (ORCID: https://orcid.org/0000-0002-7141-4687)
- Keli Yang (ORCID: https://orcid.org/0000-0003-0563-868X)
- Qing Yang (ORCID: https://orcid.org/0000-0002-9730-0901)
- Peilin Zhu
- Yujuan Guan (ORCID: https://orcid.org/0000-0001-6499-599X)
- Mengya Zang
Institutions
- Third People's Hospital of Chengdu (CN)
- Nanfang Hospital (CN)
- Zhuhai People's Hospital (CN)
- Huizhou Central People's Hospital (CN)
- Guangzhou Eighth People's Hospital (CN)
- Southwest Jiaotong University (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Liver International
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1111/liv.70066
- Citations
- 5
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 6.77
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China